"This is Sildenafil."

"I can't tell anything."

"You guys talk about this medicine, it's really interesting. A small thing can sell for hundreds of millions of dollars."

A group of laymen surrounded the raw materials of sildenafil and exclaimed bursts of emotion.

Sildenafil used for clinical trials does not require staining or anything else, and uses pure white starch and a little raw material to condense it into small tablets, which has neither taste nor appearance.

If medical experts discuss with each other, they can probably tell you something new about acetylcholine.

However, in the eyes of a group of bankers who deal with money all day long, this thing is false.

"Professor Yang is here." Someone saw Yang Rui and immediately shouted.

Several bank officials from China Agricultural Construction Engineering immediately straightened their backs and showed cordial smiles.

"Professor Yang is here."

"Congratulations on making the medicine."

"I wish you a successful trial."

Several cadres were like wishing New Year greetings, bowing and speaking auspicious words.

What everyone said is indeed sincere.

Although Pfizer eventually sold sildenafil to Yang Rui, it offered a high price, requiring an additional $180 million! And it was a milestone - if it made a finished antihypertensive drug, no matter it was launched in any country around the world, it would have to add $200 million, and then it would have to add $200 million in Europe or the United States.

It means that if anti-pressure drugs made of sildenafil start to be sold in the United States, Pfizer will take away $580 million no matter how much it is sold.

This is not over yet. If the sales are good, that is, the annual sales exceed 100 million US dollars, Pfizer will take 18% - 18% of the sales, and exchange it into the profit, which will be 20 to 30%, and it will be a milestone... If the sales exceed 1 billion US dollars and become a bombshell, Pfizer will take 25% of the sales revenue.

It's simply crazy.

To be honest, such a price can be offered by Pfizer.

That is, Yang Rui can give it.

If it is a pharmaceutical company like Jilikang, it may not necessarily have such courage.

The highest state of milestone is US$580 million, plus 25% of sales. The latter achieves sales of over US$1 billion, equivalent to US$250 million a year. The patent period for 15 consecutive years is 3.8 billion but not upward.

A patented compound that has just passed the first phase of clinical practice was sold for US$180 million and a 3.8 billion-dollar launch. It is one of the best-selling prices in the pharmaceutical industry, which has not arrived for 90 years.

This was the result of Yang Rui's argument. Of course, in order to focus the milestone on one point of anti-compression, Yang Rui also put some water a little.

Nevertheless, as a compound, this price is high enough.

Even if it is a finished drug, it is enough to sell hundreds of millions of dollars.

Double-digit trading is not very common.

Even foreign companies such as JALIC have rarely given such a big milestone transaction. For example, Yang Rui's deferrosterone, the milestone is just the starting price of sildenafil, and he still sells it with 7 active compounds.

This is how large pharmaceutical companies are, on the one hand, squeezing small biotech companies, and on the other hand, filling the market space with strong capital.

If it weren't for the big background of the Chinese market, Yang Rui wouldn't even want to raise a high price.

Of course, the current high prices are not a problem for Yang Rui.

All milestones are aimed at the antihypertensive effect of sildenafil and not other indications. Although Pfizer was not willing to sign the contract like this, he also accepted it with a pinch of his nose.

In fact, most drugs have additional effects. In professional terms, they can target other indications.

Simply put, the side effects of drugs can be used as new indications for drugs.

For example, the most common diarrhea.

Diarrhea is a side effect of many drugs, but if diarrhea is effective, drugs that are prone to diarrhea can naturally be used as laxatives.

On the other hand, some drugs can cause constipation in patients. So, if the constipation is effective, can it be used as antidiarrhea medicine?

For example, among the common side effects of antihypertensive drugs, tachycardia is often found. This is not good for many patients, especially elderly patients, but for patients with bradycardia, this is not a good thing. So, Dada, a drug that can treat bradycardia is freshly released, and its side effect is lowering blood pressure...

By the same token, the side effect of some drugs is to lower the heart rhythm, so it can work again for patients with tachycardia.

It can be seen that it is impossible for panacea to appear in the era of chemical drugs.

Your medicine cannot cause diarrhea and stop diarrhea. It also cannot lower blood pressure and increase blood pressure, improve heart rhythm and lower heart rhythm.

Aspirin is already a magical medicine. It can prevent inflammation, pain, and treat colds, inhibit platelets and prevent strokes. Even so, try feeding aspirin to the nobles suffering from hemophilia. The other party is willing to break eight scepters for it, so that you can compensate for the gems on it.

For pharmaceutical companies, developing new indications for a drug is a matter of increasing profits.

Because animal experiments and phase one and two clinical stages need not be done, as long as it proves its efficacy in phase three clinical stages, the cost is relatively low.

However, not every drug is a magical drug for aspirin. Not many drugs that develop new indications can perform well, so sales are naturally not easy to increase.

On the other hand, the patent period is not endless. The general patent period of a drug is slightly more than 15 years. The extra part is usually the additional patent period applied for, but it is also single-digit. In other words, there are very few patent drugs that can monopolize the sale of 25 years.

To develop new indications, the "slightly more" part is added, which is equivalent to using subsequent costs such as the third and fourth phases of clinical phases to exchange for a single-digit patent period increase. Is it cost-effective or not?

Most of the time, developing new indications is not so much a new use of drugs, but rather a little trick for pharmaceutical companies to extend their patent period.

Think about it more deeply, the new indication of a drug is equivalent to side effects. The better the efficacy of the new indication, the stronger the side effects are, the more clear. For a drug, this is a double-edged sword. Pharmaceutical companies would rather ask for a drug with minimal side effects and cannot find a new indication than ask for a drug with extremely strong side effects and multiple new indications.

For example, the original indication of a drug is equivalent to the box office of the theater, which is the main method for companies to make money. The new indication is equivalent to the sales revenue of DVDs, Blu-ray discs, peripherals, etc. Some companies are good at these and make money through this point, but after all, it is not mainstream and unstable.

With Yang Rui's insistence, Pfizer gave up part of its later profits and focused on the main revenue part, which also had its own routine.

In terms of profit and loss alone, they have already made a profit from the date Yang Rui’s $180 million in payment, and the rest are all net profits.

Of course, it is impossible for Yang Rui to take out $180 million in one go.

Through the coordination of several bigwigs, Yang Rui borrowed the money from the four major banks of the Industrial and Political Consultative Conference in the name of Huarui Company. Each of them bears tens of millions of quotas, and each of them is so shocked that his face is pale.

Not only that, Yang Rui also had no money to give the milestone of $200 million and $200 million in the later stage - the milestone that needs to be given when it goes public is no matter how much sales it is, it is rare to make drugs with annual sales of $200 million in the early stage.

Naturally, Pfizer cannot let its carefully designed milestones be wasted. Not to mention that Yang Rui doesn’t have that much money, it’s not possible to have it. The development cycle of a drug is often calculated in ten years. What should he do if he spends his money during this period?

Therefore, the Workers, Peasants and China Construction Corporation also needs to provide guarantees to Yang Rui.

In the bank's view, the total amount of US$580 million is much greater than that of Yang Rui.

This can be seen from their attention to the Clinical Trial Center of Hedong University. All four major banks sent special personnel from their headquarters to take charge of this matter. After the repeated experiments of animal experiments and clinical phase I was over, deputy general managers came to inspect.

There is no way. Although the country has gradually become a little money in the past two years and can afford tens of millions of dollars in funding, the expenditure of hundreds of millions of dollars is still very impressive. What can be compared with this is some basic project construction, such as railway, highway, bridge, telecommunications, power stations, etc.

Compared with those projects that can be seen and touched and can be charged if built, the research and development of sildenafil is really not worry-free.

Yang Rui was not prepared to let them worry and prevent a three-game sex:

"No one dares to say 100% of scientific research. We will do our best, and everyone should also be open-minded."

"Although our clinical trial center has just been built and lacks experience, as long as we seize the opportunity, we will soon become a mature team."

"The animal experiments and phase I clinical trials of sildenafil are very good, and phase II is a completely unfamiliar blank field, and foreigners have never done it. We are creating history every step. Please witness it with me."

Several senior officials from the bank were going crazy.

When I went to the loan company to inspect it, even if they had no meal, they would pat their chest and spit out some fresh abalone to prove it.

Is this the attitude you are doing scientific research?

Can you have some confidence?

In the past, loan companies made us come with confidence.

Witness history?

Who wants to witness history?

Hundreds of millions of dollars!

It's enough to visit Paris!

Paris……

Milan...

Long legs...

Baked elbows...

Bikini…

Blonde hair and blue eyes...
Chapter completed!